Company profile
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was
- CEO
- Mr. Eric A. Adams B.S. Chem., M.I.B.
- Headquarters
- Vancouver, BC, Canada
- Employees
- 6
- IPO date
- Nov 12, 2020
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic